Orion Pharma Limited (DSE:ORIONPHARM)
Bangladesh · Delayed Price · Currency is BDT 31.80
+0.40 (1.27%)
At close: Jul 31, 2025
United States Steel Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2016 - 2020 |
| 6,192 | 10,621 | 13,927 | 9,662 | 10,833 | 7,648 | Upgrade | |
Revenue Growth (YoY) | -46.14% | -23.74% | 44.14% | -10.81% | 41.64% | -12.15% | Upgrade |
Cost of Revenue | 4,400 | 8,348 | 11,652 | 7,693 | 8,198 | 5,075 | Upgrade |
Gross Profit | 1,792 | 2,273 | 2,275 | 1,969 | 2,635 | 2,573 | Upgrade |
Selling, General & Admin | 1,231 | 1,344 | 1,282 | 1,294 | 1,138 | 1,026 | Upgrade |
Other Operating Expenses | - | - | - | - | -41.7 | -5.44 | Upgrade |
Operating Expenses | 1,231 | 1,344 | 1,282 | 1,294 | 1,096 | 1,021 | Upgrade |
Operating Income | 561.83 | 929.02 | 992.96 | 675.12 | 1,538 | 1,552 | Upgrade |
Interest Expense | -529.47 | -393.38 | -148.29 | -173.23 | -223.43 | -717.01 | Upgrade |
Interest & Investment Income | 10.18 | 5.07 | 3.31 | 638.31 | 3.19 | 33.79 | Upgrade |
Earnings From Equity Investments | 8.99 | 9.21 | 9.13 | 9.3 | 6.07 | 6.47 | Upgrade |
Currency Exchange Gain (Loss) | 0.71 | 0.71 | 0.89 | 0.62 | 1.23 | 1.71 | Upgrade |
Other Non Operating Income (Expenses) | -20.37 | -14.75 | -16.91 | -86.74 | -131.51 | -75.22 | Upgrade |
EBT Excluding Unusual Items | 31.88 | 535.89 | 841.09 | 1,063 | 1,194 | 801.85 | Upgrade |
Gain (Loss) on Sale of Investments | -2.82 | -2.86 | 0.21 | 0.08 | -5.93 | -0.05 | Upgrade |
Pretax Income | 29.06 | 533.03 | 841.3 | 1,063 | 1,193 | 802 | Upgrade |
Income Tax Expense | 173.15 | 181.26 | 147.07 | 172.71 | 68.51 | 64.95 | Upgrade |
Earnings From Continuing Operations | -144.09 | 351.77 | 694.23 | 890.75 | 1,125 | 737.05 | Upgrade |
Minority Interest in Earnings | 34.7 | -33.65 | -53.29 | -44.67 | -185.68 | -71.36 | Upgrade |
Net Income | -109.39 | 318.12 | 640.94 | 846.08 | 939.06 | 665.69 | Upgrade |
Net Income to Common | -109.39 | 318.12 | 640.94 | 846.08 | 939.06 | 665.69 | Upgrade |
Net Income Growth | - | -50.37% | -24.25% | -9.90% | 41.07% | -24.56% | Upgrade |
Shares Outstanding (Basic) | 234 | 234 | 234 | 234 | 234 | 234 | Upgrade |
Shares Outstanding (Diluted) | 234 | 234 | 234 | 234 | 234 | 234 | Upgrade |
EPS (Basic) | -0.47 | 1.36 | 2.74 | 3.62 | 4.01 | 2.84 | Upgrade |
EPS (Diluted) | -0.47 | 1.36 | 2.74 | 3.62 | 4.01 | 2.84 | Upgrade |
EPS Growth | - | -50.37% | -24.25% | -9.90% | 41.07% | -24.56% | Upgrade |
Free Cash Flow | 49.24 | -289.06 | -1,366 | -1,505 | -1,685 | 338.88 | Upgrade |
Free Cash Flow Per Share | 0.21 | -1.24 | -5.84 | -6.43 | -7.20 | 1.45 | Upgrade |
Dividend Per Share | 1.000 | 1.000 | 1.000 | 1.000 | 1.200 | 1.000 | Upgrade |
Dividend Growth | - | - | - | -16.67% | 20.00% | -33.33% | Upgrade |
Gross Margin | 28.94% | 21.40% | 16.33% | 20.38% | 24.32% | 33.64% | Upgrade |
Operating Margin | 9.07% | 8.75% | 7.13% | 6.99% | 14.20% | 20.29% | Upgrade |
Profit Margin | -1.77% | 3.00% | 4.60% | 8.76% | 8.67% | 8.70% | Upgrade |
Free Cash Flow Margin | 0.80% | -2.72% | -9.81% | -15.58% | -15.56% | 4.43% | Upgrade |
EBITDA | 1,185 | 1,500 | 1,574 | 1,148 | 2,529 | 2,461 | Upgrade |
EBITDA Margin | 19.14% | 14.12% | 11.30% | 11.88% | 23.34% | 32.19% | Upgrade |
D&A For EBITDA | 623.44 | 570.84 | 580.89 | 472.83 | 990.2 | 909.36 | Upgrade |
EBIT | 561.83 | 929.02 | 992.96 | 675.12 | 1,538 | 1,552 | Upgrade |
EBIT Margin | 9.07% | 8.75% | 7.13% | 6.99% | 14.20% | 20.29% | Upgrade |
Effective Tax Rate | 595.92% | 34.01% | 17.48% | 16.24% | 5.74% | 8.10% | Upgrade |
Advertising Expenses | - | 26.24 | 20.53 | 19.65 | 21.74 | 26.41 | Upgrade |
Updated Feb 1, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.